Izotropic Launches "Breast Imaging News" Page on BreastCT.com

Vancouver, British Columbia, and Sacramento, California--(Newsfile Corp. - October 28, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce the launch of the "Breast Imaging News" section on BreastCT.com - a timely and strategic addition to the Company's educational and awareness website.

This new page provides regular and curated coverage of key events across the breast imaging landscape, including clinical trials, peer-reviewed studies, mergers & acquisitions, and relevant policy or insurance updates. Each article is paired with clear take-aways and, importantly, a connection back to Izotropic's flagship device, the IzoView Breast CT platform.

About Izotropic:

More information about Izotropic Corporation can be found on its corporate website at izocorp.com, its educational website at breastct.com, and by reviewing its profile on SEDAR at sedarplus.ca.

Forward-Looking Statements:

This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.

These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.

Contacts:

Robert Thast, Interim Chief Executive Officer
Telephone: [phone] or 1-833-IZOCORP ext. 1
Email: [e-mail]

James Gagnon, International Communications
Telephone: [phone] or 1-833-IZOCORP ext. 2
Email: [e-mail]

General and Corporate Inquiries
Telephone: [phone] or 1-833-IZOCORP ext. 3
Email: [e-mail]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272144

The Izotropic Corporation Stock at the time of publication of the news with a fall of -2,69 % to 0,289EUR on Tradegate stock exchange (27. Oktober 2025, 22:26 Uhr).